Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 26,082 shares of the company's Class A Common Stock on August 15, 2024. The transaction was carried out at a price of $6.69 per share, resulting in a total value of approximately $174,488. Following the sale, Gibson directly holds 732,656 shares in the company. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.

Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 26,082 shares of the company's Class A Common Stock on August 15, 2024. The transaction was carried out at a price of $6.69 per share, resulting in a total value of approximately $174,488. Following the sale, Gibson directly holds 732,656 shares in the company. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.